A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Inclusion Criteria:

   - Participant has diagnosed cancer of pancreas with biopsy and/or radiography, with a
   life expectancy of at least 5 months at screening

   - Participant's pancreatic cancer must involve the head and/or neck of the pancreas

   - Confirmed exocrine pancreatic insufficiency (EPI) as evidenced by fecal elastase-1
   (FE-1) ≤ 150 µg/g stool at screening

   - A positive Sudan stain for participants without history of fat malabsorption (fat
   malabsorption is defined as clinical steatorrhea, or measured stool fat > 7 g/day, or
   positive stool results by Sudan stain) within 1 week of screening -- Positive stool
   results are defined as increased level of neutral OR total fats

Exclusion Criteria:

   - Participant has neuroendocrine pancreatic cancer

   - Participant has fibrosing colonopathy

   - Participant has any other malignancy within 1 year of screening

   - Participant has uncontrolled gout, including those with a recent flare within 60 days
   of screening

   - Participant has other significant organ or bone marrow abnormality within 60 days of
   screening